Source: Annual Congress 2003 - Cell signalling and cytokines in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Giuliani, L. Serpero, L. Petecchia, R. Sale, F. Sabatini, M. Silvestri, P. Di Blasi, G. A. Rossi (Genoa, Verona, Italy). Inhibitory activity of fluticasone propionate (FP) and salmeterol (SAL) on TGF-β–induced expression of α-smooth muscle actin (α-SMA) by human primary airway fibroblasts (Fbs). Eur Respir J 2003; 22: Suppl. 45, 191

Member's Comments

No comment yet.

Related content which might interest you: Inhibitory activity of fluticasone propionate (FP), on the constitutive or cytokine-induced bronchial epithelial cell (HBECs) functions in vitro Source: Eur Respir J 2003; 22: Suppl. 45, 76s Year: 2003 Modulation of TNFα-induced ICAM-1 expression in a human bronchial epithelial cell line (Beas-2B) by roflumilast N-oxide (RNO), salmeterol (Sal) and budesonide (Bud) Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II Year: 2007 The inhibitory activity of fluticasone propionate (FP) on human bronchial epithelial cell (HBECs) functions in vitro is related to the intensity of the target cell response to stimuli (FLIC 24) Source: Eur Respir J 2002; 20: Suppl. 38, 91s Year: 2002 Nasal fibroblast functions involved in airway inflammation and remodelling are downregulated by fluticasone propionate (FP) Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001 Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Budesonide and formoterol differentially modulate the expression of C/EBP-alpha and calreticulin in airway smooth muscle (ASM) cells Source: Eur Respir J 2006; 28: Suppl. 50, 756s Year: 2006 Inhibitory activities of fluticasone propionate and salmeterol on airway epithelial cell functions (FLIC24): adhesion molecule expression and cytokine release Source: Eur Respir J 2001; 18: Suppl. 33, 246s Year: 2001 Effect of switching from high dose fluticasone propionate (FP) to FP/salmeterol (FSC) on airway inflammation in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 44s Year: 2004 TGFβ-induced proteoglycan production and α-smooth muscle actin expression in cultured human lung fibroblasts is inhibited by combination of budesonide and formoterol Source: Eur Respir J 2004; 24: Suppl. 48, 251s Year: 2004 Endothelin receptor B (ETBR) dependent GM-CSF mRNA stabilization explains the higher efficacy of bosentan vs. ambrisentan in the reduction of GM-CSF release from human airway smooth muscle cells (HASMCs) Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011 Modulation of bradykinin (BK)-induced lung fibroblast proliferation and differentiation by budesonide (Bud) and formoterol (Form) involves the inhibition of ERK1/2 phosphorylation and Ca2+ mobilization Source: Annual Congress 2009 - Translational models of lung disease Year: 2009 Anti-inflammatory effect of the combination of a long acting beta2-agonist (salmeterol) and a corticosteroid (fluticasone propionate) on human airway epithelial cells following Staphylococcus aureus infection Source: Eur Respir J 2005; 26: Suppl. 49, 98s Year: 2005 In vitro modulation of the cytokine-induced human bronchial epithelial cell (HBEC) functions by ciclesonide (CIC) Source: Eur Respir J 2004; 24: Suppl. 48, 346s Year: 2004 The inhibitory effect of formoterol and salmeterol on the IP-10 (CXCL10) in bronchial epithelial cells Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009 Evidence for a non-β2-adrenoceptor (β2AR) binding site in human lung tissue for the long acting β2-agonist (LABA) vilanterol Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 The effect of salmeterol/fluticasone propionate (SFC) on bronchial mucosal neutrophils and IL-8 gene expression in COPD Source: Eur Respir J 2007; 30: Suppl. 51, 354s Year: 2007 The combination salmeterol (S) + fluticasone propionate (F) in mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001 Higher cellular retention and activity after pulse exposure by budesonide (BUD) than fluticasone propionate (FP) and mometasone furoate (MF) Source: Eur Respir J 2001; 18: Suppl. 33, 158s Year: 2001 Anti-inflammatory effect of the combination of a long acting β2-agonist (salmeterol) and a corticosteroid (fluticasone propionate) on human airway epithelial cells following staphylococcus aureus virulence factors challenge Source: Eur Respir J 2006; 28: Suppl. 50, 104s Year: 2006 A comparison of salmeterol xinafoate (SX) plus fluticasone propionate (FP) and slow-release theophylline (Theo) plus FP in the treatment of stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 31s Year: 2006